Savara (SVRA) Amortization of Deferred Charges (2015 - 2026)

Savara's (SVRA) quarterly Amortization of Deferred Charges came in at $42000.0 in Q1 2026, down 40.0% year-on-year from $70000.0 in Q1 2025, and down 87.46% on a QoQ basis from $335000.0 in Q4 2025.

Savara (SVRA) Amortization of Deferred Charges (2015 - 2026) Analysis & Trends

Savara (SVRA) has 12 years of Amortization of Deferred Charges data on file, last reported at $42000.0 in Q1 2026.

  • On a quarterly basis, Amortization of Deferred Charges fell 40.0% year-over-year to $42000.0 in Q1 2026; TTM through Mar 2026 was $425000.0, a 55.68% increase from a year earlier, with the FY2025 full-year figure at $453000.0, up 67.16% from the prior year.
  • Amortization of Deferred Charges for Q1 2026 stood at $42000.0, down from $335000.0 in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for SVRA reached as high as $335000.0 in Q4 2025 and fell as low as -$87000.0 in Q2 2022.
  • Historically, Amortization of Deferred Charges has averaged $69000.0 across 5 years, with a median of $68000.0 in 2023.
  • Across the five-year window, Amortization of Deferred Charges slumped 163.5% in 2022 and surged 4200.0% in 2025, its largest moves.
  • Year by year, Amortization of Deferred Charges stood at $35000.0 in 2022, then surged by 94.29% to $68000.0 in 2023, then changed by 0.0% to $68000.0 in 2024, then jumped by 392.65% to $335000.0 in 2025, then sank by 87.46% to $42000.0 in 2026.
  • Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $42000.0 in Q1 2026, $335000.0 in Q4 2025, and -$81000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,200.25 Bn 66,199.96 Bn -
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 471.75 Bn 466.96 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.94 Bn 114.69 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.87 Bn 61.12 Bn 3.31 Bn
7 Belite Bio 62.43 Bn 62.43 Bn -
8 Argenx Se 55.86 Bn 50.68 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn
10 Savara 1.39 Bn 1.39 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 42,000.00
Mar 31, 2026 42,000.00
Dec 31, 2025 335,000.00
Dec 31, 2025 335,000.00
Sep 30, 2025 -81,000.00
Sep 30, 2025 -81,000.00
Jun 30, 2025 129,000.00
Jun 30, 2025 129,000.00
Mar 31, 2025 70,000.00
Mar 31, 2025 70,000.00
Dec 31, 2024 68,000.00
Dec 31, 2024 68,000.00
Sep 30, 2024 132,000.00
Sep 30, 2024 132,000.00
Jun 30, 2024 3,000.00
Jun 30, 2024 3,000.00
Mar 31, 2024 68,000.00
Mar 31, 2024 68,000.00
Dec 31, 2023 68,000.00
Dec 31, 2023 68,000.00